Lilly to Invest $2.1 Billion in New Indiana Manufacturing Facilities
Eli Lilly and Company plans to build two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
Eli Lilly and Company (Lilly) announced a $2.1 billion investment in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County. According to a company press release, the sites are intended to increase Lilly's manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines.
“More than 146 years after our founding, Lilly remains committed to investing and innovating in Indiana," said David A. Ricks, Lilly's chair and CEO, in the company press release. "These new sites will add capacity in support of our growing pipeline of innovative medicines, while also creating more high-tech jobs for Hoosiers. We are pleased to be a founding investor at the LEAP Lebanon Innovation District."
This move follows Lilly’s 2019 expansion in Indiana, which saw $2.5 billion invested over five years. According to the release, this brought the current number of Lilly manufacturing employees to 3,700, while the current project is slated to add an additional 500 new Lilly roles and four indirect jobs for every Lilly position created.
"Lilly has been an anchor in Indiana's economy for generations, and this announcement means they will continue to be here for generations," said Indiana governor, Eric J. Holcomb, in the press release. "I am incredibly proud Lilly continues to make exciting investments in Indiana that will better the lives and opportunities of Hoosiers for decades to come. And in turn, the very research and pharmaceutical manufacturing spearheaded here in our state will improve lives worldwide."
Source: Eli Lilly and Company
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
